Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 259

1.

Identification of a common immune regulatory pathway induced by small heat shock proteins, amyloid fibrils, and nicotine.

Rothbard JB, Rothbard JJ, Soares L, Fathman CG, Steinman L.

Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):7081-7086. doi: 10.1073/pnas.1804599115. Epub 2018 Jun 18.

PMID:
29915045
2.

Impact of blood collection and processing on peripheral blood gene expression profiling in type 1 diabetes.

Yip L, Fuhlbrigge R, Atkinson MA, Fathman CG.

BMC Genomics. 2017 Aug 18;18(1):636. doi: 10.1186/s12864-017-3949-2.

3.

Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity.

Slight-Webb S, Lu R, Ritterhouse LL, Munroe ME, Maecker HT, Fathman CG, Utz PJ, Merrill JT, Guthridge JM, James JA.

Arthritis Rheumatol. 2016 Oct;68(10):2492-502. doi: 10.1002/art.39706.

4.

Expression-Based Genome-Wide Association Study Links Vitamin D-Binding Protein With Autoantigenicity in Type 1 Diabetes.

Kodama K, Zhao Z, Toda K, Yip L, Fuhlbrigge R, Miao D, Fathman CG, Yamada S, Butte AJ, Yu L.

Diabetes. 2016 May;65(5):1341-9. doi: 10.2337/db15-1308. Epub 2016 Mar 16.

5.

Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes.

Creusot RJ, Battaglia M, Roncarolo MG, Fathman CG.

Stem Cells. 2016 Apr;34(4):809-19. doi: 10.1002/stem.2290. Epub 2016 Feb 9. Review.

6.

Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease.

Kurnellas MP, Ghosn EE, Schartner JM, Baker J, Rothbard JJ, Negrin RS, Herzenberg LA, Fathman CG, Steinman L, Rothbard JB.

Proc Natl Acad Sci U S A. 2015 Dec 8;112(49):15016-23. doi: 10.1073/pnas.1521206112. Epub 2015 Nov 30.

7.

Large-Scale and Comprehensive Immune Profiling and Functional Analysis of Normal Human Aging.

Whiting CC, Siebert J, Newman AM, Du HW, Alizadeh AA, Goronzy J, Weyand CM, Krishnan E, Fathman CG, Maecker HT.

PLoS One. 2015 Jul 21;10(7):e0133627. doi: 10.1371/journal.pone.0133627. eCollection 2015.

8.

Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.

Nair N, Mei HE, Chen SY, Hale M, Nolan GP, Maecker HT, Genovese M, Fathman CG, Whiting CC.

Arthritis Res Ther. 2015 May 18;17:127. doi: 10.1186/s13075-015-0644-z. Review.

9.

Pillars article: A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000. 100: 655-669.

Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH.

J Immunol. 2015 Apr 1;194(7):2961-75. No abstract available.

10.

Inflammation and hyperglycemia mediate Deaf1 splicing in the pancreatic lymph nodes via distinct pathways during type 1 diabetes.

Yip L, Fuhlbrigge R, Taylor C, Creusot RJ, Nishikawa-Matsumura T, Whiting CC, Schartner JM, Akter R, von Herrath M, Fathman CG.

Diabetes. 2015 Feb;64(2):604-17. doi: 10.2337/db14-0803. Epub 2014 Sep 3.

11.

Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease.

Kurnellas MP, Schartner JM, Fathman CG, Jagger A, Steinman L, Rothbard JB.

J Exp Med. 2014 Aug 25;211(9):1847-56. doi: 10.1084/jem.20140107. Epub 2014 Jul 29.

12.

Vitamin d deficiency in a multiethnic healthy control cohort and altered immune response in vitamin D deficient European-American healthy controls.

Ritterhouse LL, Lu R, Shah HB, Robertson JM, Fife DA, Maecker HT, Du H, Fathman CG, Chakravarty EF, Scofield RH, Kamen DL, Guthridge JM, James JA.

PLoS One. 2014 Apr 11;9(4):e94500. doi: 10.1371/journal.pone.0094500. eCollection 2014.

13.

Type 1 diabetes in mice and men: gene expression profiling to investigate disease pathogenesis.

Yip L, Fathman CG.

Immunol Res. 2014 May;58(2-3):340-50. doi: 10.1007/s12026-014-8501-8. Review.

PMID:
24682832
14.

Poly-L-arginine topical lotion tested in a mouse model for frostbite injury.

Auerbach LJ, DeClerk BK, Fathman CG, Gurtner GC, Auerbach PS.

Wilderness Environ Med. 2014 Jun;25(2):160-5. doi: 10.1016/j.wem.2014.01.006. Epub 2014 Mar 13.

PMID:
24631228
15.

It's time to bring dendritic cell therapy to type 1 diabetes.

Creusot RJ, Giannoukakis N, Trucco M, Clare-Salzler MJ, Fathman CG.

Diabetes. 2014 Jan;63(1):20-30. doi: 10.2337/db13-0886. Review. No abstract available.

16.

Diminished adenosine A1 receptor expression in pancreatic α-cells may contribute to the pathology of type 1 diabetes.

Yip L, Taylor C, Whiting CC, Fathman CG.

Diabetes. 2013 Dec;62(12):4208-19. doi: 10.2337/db13-0614.

17.

Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines.

Junttila IS, Creusot RJ, Moraga I, Bates DL, Wong MT, Alonso MN, Suhoski MM, Lupardus P, Meier-Schellersheim M, Engleman EG, Utz PJ, Fathman CG, Paul WE, Garcia KC.

Nat Chem Biol. 2012 Dec;8(12):990-8. doi: 10.1038/nchembio.1096. Epub 2012 Oct 28.

18.

Reduced DEAF1 function during type 1 diabetes inhibits translation in lymph node stromal cells by suppressing Eif4g3.

Yip L, Creusot RJ, Pager CT, Sarnow P, Fathman CG.

J Mol Cell Biol. 2013 Apr;5(2):99-110. doi: 10.1093/jmcb/mjs052. Epub 2012 Aug 24.

19.

New tools for classification and monitoring of autoimmune diseases.

Maecker HT, Lindstrom TM, Robinson WH, Utz PJ, Hale M, Boyd SD, Shen-Orr SS, Fathman CG.

Nat Rev Rheumatol. 2012 May 31;8(6):317-28. doi: 10.1038/nrrheum.2012.66. Review. Erratum in: Nat Rev Rheumatol. 2012 Oct;8(10):562.

20.

Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.

Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, Pande VS, Fathman CG, Boyman O, Garcia KC.

Nature. 2012 Mar 25;484(7395):529-33. doi: 10.1038/nature10975.

21.

Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.

Rothbard JB, Kurnellas MP, Brownell S, Adams CM, Su L, Axtell RC, Chen R, Fathman CG, Robinson WH, Steinman L.

J Biol Chem. 2012 Mar 23;287(13):9708-21. doi: 10.1074/jbc.M111.337691. Epub 2012 Feb 3.

22.

Differential mTOR and ERK pathway utilization by effector CD4 T cells suggests combinatorial drug therapy of arthritis.

Lin JT, Stein EA, Wong MT, Kalpathy KJ, Su LL, Utz PJ, Robinson WH, Fathman CG.

Clin Immunol. 2012 Feb;142(2):127-38. doi: 10.1016/j.clim.2011.09.008. Epub 2011 Oct 1.

23.

Dengue-2 structural proteins associate with human proteins to produce a coagulation and innate immune response biased interactome.

Folly BB, Weffort-Santos AM, Fathman CG, Soares LR.

BMC Infect Dis. 2011 Jan 31;11:34. doi: 10.1186/1471-2334-11-34.

24.

GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness.

Whiting CC, Su LL, Lin JT, Fathman CG.

FEBS J. 2011 Jan;278(1):47-58. doi: 10.1111/j.1742-4658.2010.07922.x. Epub 2010 Nov 16. Review.

25.

A model for harmonizing flow cytometry in clinical trials.

Maecker HT, McCoy JP Jr; FOCIS Human Immunophenotyping Consortium, Amos M, Elliott J, Gaigalas A, Wang L, Aranda R, Banchereau J, Boshoff C, Braun J, Korin Y, Reed E, Cho J, Hafler D, Davis M, Fathman CG, Robinson W, Denny T, Weinhold K, Desai B, Diamond B, Gregersen P, Di Meglio P, Nestle FO, Peakman M, Villanova F, Ferbas J, Field E, Kantor A, Kawabata T, Komocsar W, Lotze M, Nepom J, Ochs H, O'Lone R, Phippard D, Plevy S, Rich S, Roederer M, Rotrosen D, Yeh JH.

Nat Immunol. 2010 Nov;11(11):975-8. doi: 10.1038/ni1110-975. Erratum in: Nat Immunol. 2010 Nov;11(11):979. DiMeglio, Paola [corrected to Di Meglio, Paola]; Nestle, Frank [corrected to Nestle, Frank O]; Villnova, Federica [corrected to Villanova, Federica]. Nat Immunol. 2011 Mar;12(3):271.

26.

A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice.

Creusot RJ, Chang P, Healey DG, Tcherepanova IY, Nicolette CA, Fathman CG.

Mol Ther. 2010 Dec;18(12):2112-20. doi: 10.1038/mt.2010.146. Epub 2010 Jul 13.

27.

New technologies for autoimmune disease monitoring.

Maecker HT, Nolan GP, Fathman CG.

Curr Opin Endocrinol Diabetes Obes. 2010 Aug;17(4):322-8. doi: 10.1097/MED.0b013e32833ada91. Review.

28.

Deaf1 isoforms control the expression of genes encoding peripheral tissue antigens in the pancreatic lymph nodes during type 1 diabetes.

Yip L, Su L, Sheng D, Chang P, Atkinson M, Czesak M, Albert PR, Collier AR, Turley SJ, Fathman CG, Creusot RJ.

Nat Immunol. 2009 Sep;10(9):1026-33. doi: 10.1038/ni.1773. Epub 2009 Aug 9.

29.

The transmembrane E3 ligase GRAIL ubiquitinates and degrades CD83 on CD4 T cells.

Su LL, Iwai H, Lin JT, Fathman CG.

J Immunol. 2009 Jul 1;183(1):438-44. doi: 10.4049/jimmunol.0900204.

30.

Naive CD4 t cell proliferation is controlled by mammalian target of rapamycin regulation of GRAIL expression.

Lin JT, Lineberry NB, Kattah MG, Su LL, Utz PJ, Fathman CG, Wu L.

J Immunol. 2009 May 15;182(10):5919-28. doi: 10.4049/jimmunol.0803986.

31.

Lymphoid-tissue-specific homing of bone-marrow-derived dendritic cells.

Creusot RJ, Yaghoubi SS, Chang P, Chia J, Contag CH, Gambhir SS, Fathman CG.

Blood. 2009 Jun 25;113(26):6638-47. doi: 10.1182/blood-2009-02-204321. Epub 2009 Apr 10.

32.

Tissue- and age-specific changes in gene expression during disease induction and progression in NOD mice.

Kodama K, Butte AJ, Creusot RJ, Su L, Sheng D, Hartnett M, Iwai H, Soares LR, Fathman CG.

Clin Immunol. 2008 Nov;129(2):195-201. doi: 10.1016/j.clim.2008.07.028. Epub 2008 Sep 17.

33.

The single subunit transmembrane E3 ligase gene related to anergy in lymphocytes (GRAIL) captures and then ubiquitinates transmembrane proteins across the cell membrane.

Lineberry N, Su L, Soares L, Fathman CG.

J Biol Chem. 2008 Oct 17;283(42):28497-505. doi: 10.1074/jbc.M805092200. Epub 2008 Aug 18.

34.

Cutting edge: The transmembrane E3 ligase GRAIL ubiquitinates the costimulatory molecule CD40 ligand during the induction of T cell anergy.

Lineberry NB, Su LL, Lin JT, Coffey GP, Seroogy CM, Fathman CG.

J Immunol. 2008 Aug 1;181(3):1622-6.

35.

Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice.

Creusot RJ, Yaghoubi SS, Kodama K, Dang DN, Dang VH, Breckpot K, Thielemans K, Gambhir SS, Fathman CG.

Clin Immunol. 2008 May;127(2):176-87. doi: 10.1016/j.clim.2007.12.009. Epub 2008 Mar 12.

36.

Multimodality imaging of T-cell hybridoma trafficking in collagen-induced arthritic mice: image-based estimation of the number of cells accumulating in mouse paws.

Yaghoubi SS, Creusot RJ, Ray P, Fathman CG, Gambhir SS.

J Biomed Opt. 2007 Nov-Dec;12(6):064025. doi: 10.1117/1.2821415.

PMID:
18163841
37.

Naive and memory T cells induce different types of graft-versus-host disease.

Dutt S, Tseng D, Ermann J, George TI, Liu YP, Davis CR, Fathman CG, Strober S.

J Immunol. 2007 Nov 15;179(10):6547-54.

39.

Molecular mechanisms of CD4+ T-cell anergy.

Fathman CG, Lineberry NB.

Nat Rev Immunol. 2007 Aug;7(8):599-609. Epub 2007 Jul 6. Review.

PMID:
17612584
40.

Preservation of self: an overview of E3 ubiquitin ligases and T cell tolerance.

Schartner JM, Fathman CG, Seroogy CM.

Semin Immunol. 2007 Jun;19(3):188-96. Epub 2007 Apr 2. Review.

PMID:
17403607
41.

GRAIL is up-regulated in CD4+ CD25+ T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype.

MacKenzie DA, Schartner J, Lin J, Timmel A, Jennens-Clough M, Fathman CG, Seroogy CM.

J Biol Chem. 2007 Mar 30;282(13):9696-702. Epub 2007 Jan 26.

42.
43.

Does our current understanding of the molecular basis of immune tolerance predict new therapies for autoimmune disease?

Tarner IH, Fathman CG.

Nat Clin Pract Rheumatol. 2006 Sep;2(9):491-9. Review.

PMID:
16951704
44.

T cell anergy: where it's LAT.

Lineberry N, Fathman CG.

Immunity. 2006 May;24(5):501-3. Review. Erratum in: Immunity. 2006 Jul;25(1):175.

45.

CYLD: deubiquitination-induced TCR signaling.

Lineberry N, Fathman CG.

Nat Immunol. 2006 Apr;7(4):369-70. No abstract available.

PMID:
16550202
46.

Developing the concept of adoptive cellular gene therapy of rheumatoid arthritis.

Tarner IH, Neumann E, Gay S, Fathman CG, Müller-Ladner U.

Autoimmun Rev. 2006 Feb;5(2):148-52. Epub 2005 Oct 3.

PMID:
16431349
47.

Cd4+Cd25+ regulatory T cells and their therapeutic potential.

Randolph DA, Fathman CG.

Annu Rev Med. 2006;57:381-402. Review.

PMID:
16409156
48.

Targeted gene therapy of autoimmune diseases: advances and prospects.

Creusot RJ, Fathman CG, Müller-Ladner U, Tarner IH.

Expert Rev Clin Immunol. 2005 Sep;1(3):385-404. doi: 10.1586/1744666X.1.3.385.

PMID:
20476990
49.

L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease.

Dutt S, Ermann J, Tseng D, Liu YP, George TI, Fathman CG, Strober S.

Blood. 2005 Dec 1;106(12):4009-15. Epub 2005 Aug 16.

50.

Molecular imaging using labeled donor tissues reveals patterns of engraftment, rejection, and survival in transplantation.

Cao YA, Bachmann MH, Beilhack A, Yang Y, Tanaka M, Swijnenburg RJ, Reeves R, Taylor-Edwards C, Schulz S, Doyle TC, Fathman CG, Robbins RC, Herzenberg LA, Negrin RS, Contag CH.

Transplantation. 2005 Jul 15;80(1):134-9.

PMID:
16003245

Supplemental Content

Loading ...
Support Center